Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13056MR)

This product GTTS-WQ13056MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13056MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4816MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ7539MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ10678MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ12020MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ300MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ6450MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ4382MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ6701MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW